Ventyx Biosciences (VTYX) Set to Announce Quarterly Earnings on Thursday

Ventyx Biosciences (NASDAQ:VTYX) is scheduled to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Ventyx Biosciences to post earnings of ($0.67) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.08. During the same quarter in the previous year, the company earned ($0.62) EPS. On average, analysts expect Ventyx Biosciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ventyx Biosciences Trading Down 2.2 %

NASDAQ:VTYX opened at $4.61 on Wednesday. The company has a 50-day moving average price of $6.02 and a 200-day moving average price of $4.72. The stock has a market cap of $324.65 million, a price-to-earnings ratio of -1.40 and a beta of 0.48. Ventyx Biosciences has a 12 month low of $1.87 and a 12 month high of $40.58.

Analyst Ratings Changes

Several research firms have weighed in on VTYX. Lifesci Capital raised Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research report on Wednesday, February 28th. Canaccord Genuity Group reduced their price target on Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. Oppenheimer raised Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price objective for the company in a research report on Tuesday, March 12th. Finally, Wells Fargo & Company raised shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $7.00 to $16.00 in a research report on Tuesday, March 12th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.